

Effects of Icosapent Ethyl on TotalÂ Ischemic Events

Journal of the American College of Cardiology
73, 2791-2802

DOI: [10.1016/j.jacc.2019.02.032](https://doi.org/10.1016/j.jacc.2019.02.032)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Predicting the effects of supplemental EPA and DHA on the omega-3 index. American Journal of Clinical Nutrition, 2019, 110, 1034-1040.	4.7	63
2	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. Journal of the American College of Cardiology, 2019, 74, 1159-1161.	2.8	79
3	PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis, 2019, 288, 146-155.	0.8	80
4	Effects of <i>n</i>-3 PUFA on endothelial function in patients with peripheral arterial disease: a randomised, placebo-controlled, double-blind trial. British Journal of Nutrition, 2019, 122, 698-706.	2.3	10
5	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	1
6	Ischemic Event Reduction and Triglycerides. Journal of the American College of Cardiology, 2019, 74, 1848-1849.	2.8	1
7	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Journal of Clinical Lipidology, 2019, 13, 860-872.	1.5	79
8	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	2.2	17
9	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. JAMA Cardiology, 2019, 4, 1214.	6.1	39
10	Understanding why REDUCE-IT was positive â€” Mechanistic overview of eicosapentaenoic acid. Progress in Cardiovascular Diseases, 2019, 62, 401-405.	3.1	15
11	Reply. Journal of the American College of Cardiology, 2019, 74, 1849-1850.	2.8	11
12	Targeting RNA to lower triglycerides: long strides from short molecules. European Heart Journal, 2019, 40, 2797-2800.	2.2	10
13	Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Current Atherosclerosis Reports, 2019, 21, 31.	4.8	8
14	Risk of Total Events With Icosapent Ethyl. Journal of the American College of Cardiology, 2019, 73, 2803-2805.	2.8	8
15	Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitationâ€”Contradictory or Complementary?. JAMA Cardiology, 2019, 4, 311.	6.1	14
16	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. European Heart Journal, 2020, 41, 86-94.	2.2	71
17	Cardiovascular risk reduction with icosapent ethyl. Current Opinion in Cardiology, 2019, 34, 721-727.	1.8	23
18	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. American Journal of Cardiovascular Drugs, 2020, 20, 11-18.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Dietary and Pharmacological Fatty Acids and Cardiovascular Health. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1030-1045.	3.6	19
20	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
21	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. European Heart Journal, 2020, 41, 2304-2312.	2.2	54
22	Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. European Heart Journal Supplements, 2020, 22, J21-J33.	0.1	7
23	When to lower triglycerides?. Current Opinion in Lipidology, 2020, 31, 238-245.	2.7	9
24	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, 199.	6.8	14
25	Omega-6 DPA and its 12-lipoxygenase-oxidized lipids regulate platelet reactivity in a nongenomic PPAR α -dependent manner. Blood Advances, 2020, 4, 4522-4537.	5.2	17
26	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary. Endocrine Practice, 2020, 26, 1196-1224.	2.1	117
27	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes and Endocrinology, 2020, 8, 949-959.	11.4	41
28	The Effect of Blood Lipids on the Left Ventricle. Journal of the American College of Cardiology, 2020, 76, 2477-2488.	2.8	26
29	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	2.2	11
30	Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease. Complementary Therapies in Medicine, 2020, 52, 102482.	2.7	12
31	Can EPA evaporate plaques?. European Heart Journal, 2020, 41, 3933-3935.	2.2	6
32	A Revolution in Omega-3 Fatty Acid Research. Journal of the American College of Cardiology, 2020, 76, 2098-2101.	2.8	21
33	The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction. Current Diabetes Reports, 2020, 20, 65.	4.2	18
34	Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. European Heart Journal Supplements, 2020, 22, J1-J2.	0.1	8
35	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. European Heart Journal, 2020, 41, 3925-3932.	2.2	257
36	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. Current Atherosclerosis Reports, 2020, 22, 67.	4.8	15

#	ARTICLE	IF	CITATIONS
37	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	10
38	Epoxy Fatty Acids Are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation. Advances in Experimental Medicine and Biology, 2020, 1274, 71-99.	1.6	38
39	Effects of Epeleuton, a Novel Synthetic Secondâ€¢Generation nâ€¢3 Fatty Acid, on Nonâ€¢Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. Journal of the American Heart Association, 2020, 9, e016334.	3.7	17
40	Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. American Journal of Preventive Cardiology, 2020, 4, 100117.	3.0	2
41	<p>Progressive Loss of Corneal Nerve Fibers and Sensitivity in Rats Modeling Obesity and Type 2 Diabetes Is Reversible with Omega-3 Fatty Acid Intervention: Supporting Cornea Analyses as a Marker for Peripheral Neuropathy and Treatment</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1367-1384.	2.4	21
42	Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults. Circulation, 2020, 141, 1778-1786.	1.6	110
43	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	3.0	16
44	Conversion of dietary polyunsaturated fats between humans and rodents: A review of allometric scaling models. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 158, 102094.	2.2	10
45	Response by Bhatt et al to Letter Regarding Article, â€œREDUCE-IT USA: Results From the 3146 Patients Randomized in the United Statesâ€¢. Circulation, 2020, 141, e834-e835.	1.6	3
46	Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial. Atherosclerosis, 2020, 305, 34-41.	0.8	7
47	Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease Through the Resolvin E1 and ChemR23 Axis. Circulation, 2020, 142, 776-789.	1.6	44
48	Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Diseaseâ€¢s â€¢ABCâ€¢s Approach. American Journal of Preventive Cardiology, 2020, 2, 100027.	3.0	6
49	Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. Future Cardiology, 2020, 16, 343-350.	1.2	0
50	Defining the Role of Icosapent Ethyl in Clinical Practice. American Journal of Cardiovascular Drugs, 2020, 20, 517-524.	2.2	1
51	Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories. Journal of the American College of Cardiology, 2020, 75, 2110-2118.	2.8	27
52	Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1135-1147.	2.4	240
53	Triglycerides and Cardiovascular Outcomesâ€¢Can We REDUCE-ITâ€¢?. International Journal of Angiology, 2020, 29, 002-011.	0.6	5
54	Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. Expert Review of Cardiovascular Therapy, 2020, 18, 175-180.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Optimum nutritional strategies for cardiovascular disease prevention and rehabilitation (BACPR). Heart, 2020, 106, 724-731.	2.9	25
56	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. The Cochrane Library, 2020, 2020, CD003177.	2.8	153
57	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacological Research, 2020, 153, 104653.	7.1	54
58	Plant and Fish Derived ω -3 PUFAs Suppress <i>Citrobacter Rodentium</i> Induced Colonic Inflammation. Molecular Nutrition and Food Research, 2020, 64, e1900873.	3.3	13
59	Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date. Vascular Health and Risk Management, 2020, Volume 16, 1-10.	2.3	10
60	Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps. Journal of the American College of Cardiology, 2020, 75, 539-555.	2.8	58
61	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open, 2020, 2, 402-415.	1.5	6
62	Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2020, 75, 2119-2121.	2.8	20
63	Inflammation and cardiovascular disease: are marine phospholipids the answer?. Food and Function, 2020, 11, 2861-2885.	4.6	65
64	The novel long noncoding RNA Lnc19959.2 modulates triglyceride metabolism-associated genes through the interaction with Purb and hnRNPA2B1. Molecular Metabolism, 2020, 37, 100996.	6.5	10
65	Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. Blood Reviews, 2021, 45, 100694.	5.7	87
66	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovascular Research, 2021, 117, 1070-1077.	3.8	45
67	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
68	Practical Guidance for Food Consumption to Prevent Cardiovascular Disease. Heart Lung and Circulation, 2021, 30, 163-179.	0.4	22
69	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e61-e63.	3.0	23
70	Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes. Atherosclerosis, 2021, 316, 58-65.	0.8	26
71	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. Annual Review of Medicine, 2021, 72, 431-446.	12.2	9
72	Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids. Journal of the American College of Cardiology, 2021, 77, 593-608.	2.8	33

#	ARTICLE	IF	CITATIONS
73	Nutraceuticals in Chronic Coronary Syndromes: Preclinical Data and Translational Experiences. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 13-25.	2.2	3
74	Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state-of-the-art. Expert Review of Clinical Pharmacology, 2021, 14, 79-93.	3.1	21
75	Higher Increase in Plasma DHA in Females Compared to Males Following EPA Supplementation May Be Influenced by a Polymorphism in ELOVL2 : An Exploratory Study. Lipids, 2021, 56, 211-228.	1.7	10
76	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Postgraduate Medicine, 2021, 133, 28-41.	2.0	10
77	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiology, 2021, 17, 155-174.	1.2	14
78	The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?. Heart International, 2021, 15, 7.	1.4	1
79	Microbiota, a New Playground for the Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Diseases. Marine Drugs, 2021, 19, 54.	4.6	12
80	Dyslipidemia in Women: Etiology and Management. Stroke Revisited, 2021, , 173-202.	0.2	3
81	The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk. Journal of Lipids, 2021, 2021, 1-5.	4.8	1
82	Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies. Current Diabetes Reviews, 2021, 17, e011221190238.	1.3	6
83	Macrophage Responses to Environmental Stimuli During Homeostasis and Disease. Endocrine Reviews, 2021, 42, 407-435.	20.1	21
84	Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 634-640.	2.6	10
85	Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study. BMJ Open, 2021, 11, e038881.	1.9	2
86	Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. Current Atherosclerosis Reports, 2021, 23, 27.	4.8	4
87	Influence of lipid-lowering drugs on inflammation: what is yet to be done?. Archives of Medical Science, 2021, , .	0.9	6
88	Lipid Lowering Drugs: Present Status and Future Developments. Current Atherosclerosis Reports, 2021, 23, 17.	4.8	41
89	Statistical methods for composite endpoints. EuroIntervention, 2021, 16, e1484-e1495.	3.2	13
90	The changing landscape of atherosclerosis. Nature, 2021, 592, 524-533.	27.8	921

#	ARTICLE	IF	CITATIONS
91	Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project. <i>European Cardiology Review</i> , 2021, 16, e16.	2.2	2
92	Umbrella Review on Non-Statin Lipid-Lowering Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110029.	2.0	11
93	The role of icosapent ethyl in cardiovascular risk reduction. <i>Current Opinion in Cardiology</i> , 2021, 36, 661-671.	1.8	3
94	Diabetes mellitus and chronic coronary syndrome. <i>МÃ-Ã¼narodnij EndokrinologÃ-Änij Å½urnal</i> , 2021, 17, 43-55.	0.4	2
95	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35
96	Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). <i>American Heart Journal</i> , 2021, 235, 54-64.	2.7	11
97	Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 177-185.	3.8	8
98	Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. <i>Journal of Clinical Medicine</i> , 2021, 10, 2495.	2.4	9
99	The Role of Micronutrients in Ageing Asia: What Can Be Implemented with the Existing Insights. <i>Nutrients</i> , 2021, 13, 2222.	4.1	9
100	A rare case of diabetic ketoacidosis presenting with severe hypertriglyceridemia requiring plasmapheresis in an adult with type-2 diabetes mellitus. <i>Medicine (United States)</i> , 2021, 100, e26237.	1.0	2
101	Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 524-532.	2.0	3
102	Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database. <i>Future Cardiology</i> , 2021, 17, 743-755.	1.2	8
103	Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis. <i>American Journal of Medicine</i> , 2021, 134, e415-e419.	1.5	9
104	Downhill hiking improves low-grade inflammation, triglycerides, body weight and glucose tolerance. <i>Scientific Reports</i> , 2021, 11, 14503.	3.3	6
105	Effects of fatty acids on T cell function: role in atherosclerosis. <i>Nature Reviews Cardiology</i> , 2021, 18, 824-837.	13.7	25
106	Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. <i>European Heart Journal Open</i> , 2021, 1, .	2.3	9
107	The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization. <i>Progress in Cardiovascular Diseases</i> , 2021, 69, 3-10.	3.1	15
108	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 38, 100997.	7.1	121

#	ARTICLE	IF	CITATIONS
109	Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Expert Opinion on Drug Safety, 2022, 21, 31-42.	2.4	7
110	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. IScience, 2021, 24, 103040.	4.1	19
111	Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA Network Open, 2021, 4, e2127573.	5.9	68
112	Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction. American Journal of Medicine, 2021, 134, 1085-1090.	1.5	27
113	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. European Heart Journal, 2022, 43, 148-149.	2.2	13
114	Methodological challenges in the analysis of recurrent events for randomised controlled trials with application to cardiovascular events in LEADER. Pharmaceutical Statistics, 2022, 21, 241-267.	1.3	9
115	Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REDuction of Atherothrombosis for Continued Health (REACH) registry. International Journal of Cardiology, 2021, 340, 96-104.	1.7	9
116	Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 173, 102337.	2.2	32
117	EPA and DHA containing phospholipids have contrasting effects on membrane structure. Journal of Lipid Research, 2021, 62, 100106.	4.2	28
118	Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. European Heart Journal Supplements, 2020, 22, J34-J48.	0.1	68
119	Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements, 2020, 22, J54-J64.	0.1	9
120	The fish-oil paradox. Current Opinion in Lipidology, 2020, 31, 356-361.	2.7	5
121	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. European Cardiology Review, 2021, 16, e40.	2.2	9
122	Essential Fatty Acids as Biomedicines in Cardiac Health. Biomedicines, 2021, 9, 1466.	3.2	18
123	Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. Journal of the American Heart Association, 2021, 10, e020377.	3.7	12
124	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537.	2.8	25
125	Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 786-788.	0.9	0
126	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2021, 144, 1845-1855.	1.6	39

#	ARTICLE	IF	CITATIONS
127	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021, 144, 1750-1759.	1.6	36
128	Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). <i>Contemporary Cardiology</i> , 2021, , 295-306.	0.1	1
129	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 104-113.	2.3	2
130	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. <i>Contemporary Cardiology</i> , 2021, , 615-636.	0.1	0
132	High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?. <i>Vascular Pharmacology</i> , 2021, 141, 106928.	2.1	7
133	Changing dietary approaches to prevent cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2020, 31, 313-323.	2.7	6
134	Effects of omega-3 polyunsaturated fatty acids supplementation for patients with cardiovascular disease risks: a dose-response meta-analysis. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 8526-8539.	0.0	0
135	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, .	4.1	1
137	Determinants of high-density lipoprotein (HDL) functions beyond proteome in Asian Indians: exploring the fatty acid profile of HDL phospholipids. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 559-570.	3.1	1
138	Dietary alpha-linolenic acid reduces platelet activation and collagen-mediated cell adhesion in sickle cell disease mice. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 375-386.	3.8	6
139	Effectiveness of a Novel Î³-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia. <i>JAMA Network Open</i> , 2022, 5, e2141898.	5.9	14
140	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, 2957.	4.1	9
141	Inflammation Resolution: Implications for Atherosclerosis. <i>Circulation Research</i> , 2022, 130, 130-148.	4.5	49
142	Non-invasive imaging as the cornerstone of cardiovascular precision medicine. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 465-475.	1.2	15
143	Substantial Impact of Eicosapentaenoic Acid on Cardiovascular Outcomes in the REDUCE-IT Trial. <i>Cardiometabolic Syndrome Journal</i> , 0, 2, .	0.6	0
144	Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842210847.	2.0	1
145	Translating a treatment for diabetic peripheral neuropathy from rodents to humans: can a case be made for fish oil and salsalate?. , 2022, , 337-348.		0
146	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. <i>JAMA Network Open</i> , 2022, 5, e2148172.	5.9	11

#	ARTICLE	IF	CITATIONS
147	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Journal of the American Heart Association, 2022, 11, e022937.	3.7	26
148	Clinical and Economic Profile of Homeless Young Adults with Stroke in the United States, 2002 – 2017. Current Problems in Cardiology, 2022, , 101190.	2.4	2
149	RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus. International Journal of Diabetes in Developing Countries, 0, , 1.	0.8	1
150	Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. , 2022, 237, 108172.		18
151	New therapeutic approaches for the treatment of hypertriglyceridemia. Herz, 2022, 47, 220-227.	1.1	3
152	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1660-1671.	2.8	36
153	The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. American Journal of Preventive Cardiology, 2022, 10, 100345.	3.0	4
154	Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management. EBioMedicine, 2022, 80, 104038.	6.1	7
156	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. American Heart Journal Plus, 2022, 17, 100148.	0.6	4
157	Killing the Culprit: Pharmacological Solutions to Get Rid of Cholesterol Crystals. Current Problems in Cardiology, 2022, 47, 101274.	2.4	1
158	Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. Journal of Clinical Lipidology, 2022, 16, 389-402.	1.5	7
159	Marine-derived n-3 fatty acids therapy for stroke. The Cochrane Library, 2022, 2022, .	2.8	0
161	Dyslipidemia in Transplant Patients: Which Therapy?. Journal of Clinical Medicine, 2022, 11, 4080.	2.4	6
162	Omega-3 and cardiovascular prevention – Is this still a choice?. Pharmacological Research, 2022, 182, 106342.	7.1	13
163	Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality. Clinical Nutrition, 2022, 41, 1798-1807.	5.0	30
164	Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid. , 2022, 240, 108237.		8
165	Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: Post Hoc Analysis From the CREDENCE Trial. Journal of the American Heart Association, 2022, 11, .	3.7	2
166	Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1 ² , Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation, 2022, 146, 372-379.	1.6	66

#	ARTICLE	IF	CITATIONS
167	Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden. <i>Heart International</i> , 2022, 16, 2.	1.4	1
168	Effect of Omega-3 fatty acids supplementation on serum level of C-reactive protein in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	10
169	Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. <i>Panminerva Medica</i> , 2023, 65, .	0.8	3
170	Association between the ratio of serum eicosapentaenoic acid to arachidonic acid and risk of coronary artery disease in young Chinese patients. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	3
171	Icosapent Ethyl for the Prevention of Cardiovascular Events. <i>EMJ Cardiology</i> , 0, , 56-65.	0.0	0
172	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Espa�ola de Cardiolog�a [Spanish Society of Cardiology] and the Sociedad Espa�ola de Diabetes [Spanish Diabetes Society]. <i>Endocrinolog�a Diabetes Y Nutrici�n (English Ed.)</i> , 2023, 70, 51-62.	0.2	0
173	Omega-3 pleiad: The multipoint anti-inflammatory strategy. <i>Critical Reviews in Food Science and Nutrition</i> , 0, , 1-16.	10.3	1
174	Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1637.	4.1	4
175	Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. <i>Current Atherosclerosis Reports</i> , 2023, 25, 1-17.	4.8	28
176	Residual risk in patients with atherosclerotic cardiovascular disease. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 22, 3382.	1.4	0
177	The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches. , 2023, , 273-309.		0
178	Intensive glucose control and recurrent cardiovascular events: 14��year follow��up investigation of the ACCORDION study. <i>Diabetes/Metabolism Research and Reviews</i> , 2023, 39, .	4.0	1
179	The Clock Is Ticking: The Imminent Need to Re-evaluate the Standard of Care in the 90-Day High-Risk Post-Acute Myocardial Infarction Period. <i>EMJ Cardiology</i> , 0, , 2-6.	0.0	0
180	Is type 2 diabetes associated dementia a microvascular early-Alzheimer��s phenotype induced by aberrations in the peripheral metabolism of lipoprotein-amyloid?. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
181	Assessing the Highest Level of Evidence from Randomized Controlled Trials in Omega-3 Research. <i>Nutrients</i> , 2023, 15, 1001.	4.1	1
182	Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE��T. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	8
183	Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements��A Narrative Review. <i>Nutrients</i> , 2023, 15, 1517.	4.1	10
184	Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 866-873.	1.2	6

#	ARTICLE	IF	CITATIONS
185	New approaches to reduce recurrent PCI: to angioplasty and beyond!. European Heart Journal Open, 2023, 3, .	2.3	0
186	REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees?. European Journal of Preventive Cardiology, 0, , .	1.8	1
187	Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China. Lipids in Health and Disease, 2023, 22, .	3.0	0
188	Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome. American Journal of Preventive Cardiology, 2023, 15, 100510.	3.0	1
189	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. Contemporary Diabetes, 2023, , 821-878.	0.0	0
190	Omega-3 Fatty Acids. , 2024, , 169-183.e3.		0
191	Micronutrient Status Among Adults in the Asia Pacific and Potential Impact on Age-Related Diseases. , 2023, , 155-181.		0
192	Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation. Journal of the American College of Cardiology, 2023, 82, 336-349.	2.8	12
193	Nutraceutical support in the prevention and treatment of cardiovascular diseases. Rational Pharmacotherapy in Cardiology, 2023, 19, 298-306.	0.8	0
194	Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
195	Generalized Pairwise Comparisons to Assess Treatment Effects. Journal of the American College of Cardiology, 2023, 82, 1360-1372.	2.8	1
196	Recurrent Events in Cardiovascular Trials. Journal of the American College of Cardiology, 2023, 82, 1445-1463.	2.8	1
197	Preventive Therapies in Peripheral Arterial Disease. Biomedicines, 2023, 11, 3157.	3.2	1
198	Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn. European Heart Journal Open, 2023, 3, .	2.3	3
199	Assessing the Efficacy of Omega-3 Fatty Acids+Statins vs. Statins Only on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of 40,991 Patients. Current Problems in Cardiology, 2024, 49, 102245.	2.4	0
200	Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. Journal of the American Heart Association, 0, , .	3.7	0
201	Effect of six month's treatment with omega-3 acid ethyl esters on long-term outcomes after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial. International Journal of Cardiology, 2024, 399, 131698.	1.7	1
202	Do patients benefit from omega-3 fatty acids?. Cardiovascular Research, 2024, 119, 2884-2901.	3.8	0

#	ARTICLE	IF	CITATIONS
203	Omega-3 fatty acids for cardiovascular event lowering. European Journal of Preventive Cardiology, 0, , .	1.8	1
204	Impact of Bempedoic Acid on Total Cardiovascular Events. JAMA Cardiology, 2024, 9, 245.	6.1	2
205	The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development. JACC Basic To Translational Science, 2024, , .	4.1	0
206	Effect of statin add-on therapy on cardiovascular mortality. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
207	Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. Journal of the American College of Cardiology, 2024, 83, 1529-1539.	2.8	0